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Mucormycosis - Dual Therapy with Prolonged Survival
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Abstract
Mucorales fungal infection is a fungal disease with potentially fatal outcomes. The most frequent
involvement in humans comes from the orders known as Mucorales and Entomophthorales.
Mucorales is more acute and has a predilection for immunocompromised patients. Mucorales are
associated with an affinity for vessels, which leads to invasion and infarction of tissue. Mucormycosis
is a devastating complication that can be a life threatening fungal invasion in many patients in an
immunocompromised state.
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Case Presentation
In 2014, a 69-year-old Panamanian female with a past medical
history of diabetes mellitus type 2 and the presence of a
pterygium on her conjunctiva had had resection a month prior
of her pterygium and placement of an amniotic membrane graft
to her left eye for which she had been treated with longterm
corticosteroids. She presented to the emergency department of
a hospital in Panama City, Panama with a history of one week of
evolution of swelling of the right side of her face, ipsilateral eye
proptosis and odynophagia. A large ulcer (3 X 4 cm) in her hard
palate was evident.

Video 1 Nasal endoscopic view of each nostril and a hard palate
ulcer with necrotic tissue in a patient with Mucormycosis.

Her labs showed anemia (hematocrit 27%), leukocytosis (15,000
cells/mL3), neutrophilia (73%), acute kidney injury (creatinine
2.0 mg/dL) and diabetic ketoacidosis with an elevated anion gap
of 16 meq/L. As part of the emergency diagnostic approach, she
had a nasal endoscopy during which they observed a necrotic
lesion in the septum with cotton-like texture at the level of the
nostrils. (Video 1)
The CT scan revealed inflammatory changes, a fluid collection
and inflammatory necrotic tissue in the masticatory space that
extended on the right to the pterygopalatine fossa and orbital
apex (Figure 1). There was involvement (anterior to posterior)
of her right eye (proptosis), compromise of intra- and extraconal fat, the medial rectus muscle, and the superior orbital
fissure, as well as asymmetry of the right cavernous sinus.
Figure 1 CT head scan with inflammatory necrotic tissue in the
masticatory space that extended to the pterygopalatine fossa and the
orbital apex. Post-surgical inflammatory changes are visible (large
single arrow) as well as invasion of infection into the right carotid artery
(line with two arrowheads).
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Figure 2
(A) Periodic acid Schiff stain (PAS) of necrotic nasal tissue showing a vessel with fungal invasion
(B) Enhancement of necrotic nasal tissue structures showing mucormycosis with silver staining (Gomori)

She was taken to the operating room three times for debridement
and cleaning of necrotic tissue. The orbit decompression was
draining pus. An open approach was performed including a
subtotal maxilectomy (palate/pterygoid lamina). It was closed
with a gingival flap of the oral palate. A tissue sample was taken
to the pathology department where it showed tubular structures
compatible with a fungus. Gomori stains and periodic acidSchiff stain findings were consistent with mucormycosis
(Figure 2).
Treatment included initially caspofungin alone without
improvement, then amphotericin B deoxycholate was added as
salvage therapy. Amphotericin B was given at a dose of 50mg
daily (1 mg/kg/day) until a total cumulative dose of 2580 mg
was given. Complications related to the medication were seen,
especially nephrotoxicity due to the amphotericin B, therefore it
was reduced to 30 mg/day (0.6 mg/kg/day).
After five months of dual antifungal therapy and multiple
debridements, risk factors related to comorbidities continued
to play an important role for lack of control of the disease.
Poor glycemic control at home, nephrotoxicity and electrolyte
disturbances complicated the outcome. She returned with a
probable cerebral vascular event secondary to extension of the
mucormycosis to the brain and died a week later.

Discussion
Rhinocerebral mucormycosis is a devastating infection with
high mortality of 35% for patients with no underlying condition
[1]. Its relationship with immunosuppression makes treatment
of this fungal infection difficult. The most frequent involvement
in humans comes from the orders known as Mucorales and
Entomophthorales [2]. Infections usually begin in the paranasal
sinuses following inhalation of sporangiospores and may
involve the orbit, palate, face, nose or brain [2]. The important
characteristic for the diagnosis of this disease is the vascular
invasion and tissue necrosis similar to what we observed in
the pathology of our patient, with wide hyphae (10-20µm), and
right-angled branching without septa.

causing at least 90% of cases related to rhinocerebral
mucormycosis [1]. Mucormycosis appears as an opportunistic
disease due to certain risk factors (Table 1). The number of
patients with predisposing risk factors has increased making the
disease more prevalent. The overall mortality rate for a diabetic
patient is as high as 44% [2]. Our patient’s main comorbidity
was the decompensation of her diabetes, which accounted for
her predisposition to, and the persistence of, her infection.
Prevention of mucormycosis can be attained with control
of diabetes mellitus by maintaining normal glycemia levels,
correcting ketoacidosis, and avoiding corticosteroid therapy.
Proper treatment with a favorable outcome depends on both
medical treatment and good initial debridement.
Mucormycosis invasiveness may be based on the availability of
iron in serum and tissue [5]. Iron will promote neurotropism
and invasion. The low pH in uncontrolled diabetes also
decreases the activity of transferrin, which results in more
free iron in the blood for Mucorales [6]. The rhinocerebral,
pulmonary and disseminated presentation of mucormycosis
all have necrosis, thrombosis and invasion of blood vessels in
common [5]. 1,3-β-D-glucan detection is not useful in this kind
of infection due to extremely low content of this molecule in
Mucorales [5,7].
It is well known that macrophages and neutrophils have an
important role in immune defense. The functional defects
caused by therapeutic interventions such as corticosteroids
play a crucial risk factor for Mucorales to infect [5]. Diabetes
alone can impair the function of neutrophils contributing to
the severity of mucormycosis in patients with ketoacidosis
[8]. Macrophages have a dimished phagocytotic effect
and neutrophils have a diminished chemotactic and
oxidative burst due to the low pH during ketoacidosis [6].
Table 1 Risk factors for acquiring mucormycosis.

Entomophthorales in the tropics are associated with chronic
conditions of the skin and subcutaneous tissue [2]. Mucorales
has an affinity for vessels and leads to invasion and infarction
of tissue [3]. Mucor species are typically avirulent due to a lack
of thermo-tolerability in the presence of a healthy host immune
system, but will manifest with disease in the presence of
immunosuppression[4]. Rhizopus orizae is the most common
isolated filamentous fungus from patients with mucormycosis
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Risk Factors for Acquiring Mucormycosis
Immunosuppression
Neutropenia
Corticosteroid therapy
HIV infection
Organ transplant
Uncontrolled Diabetes/Diabetic ketoacidosis
Chronic metabolic acidosis
Treatment with deferoxamine
2

One study found that the host receptor, glucose regulated
protein (GPR78), facilitates the invasion of human endothelial
cells by R. oryzae due to the presence of high iron and glucose
concentrations [9]. In the diabetic murine model, there was a
direct relationship between an increased expression of this
protein and the damage of endothelial cells [9].
This is a disease condition without many therapeutic options due
to the severity of disease. The standard treatment recommended
in rhinocerebral mucormycosis is amphotericin B with
debridement, but the combined treatment of amphotericin
B plus either an echinocandin or an azole with debridement
was shown to improve survival in three cases [10,11]. Drugs
that have an FDA approved indication for mucormycosis are
amphotericin B with its lipid derivatives, and isavuconazonium
sulfate, the pro-drug of isavuconazole, which was not available
until 2015 (a year after this patient’s death).
The genome sequence of R. oryzae has led to the discovery of
genes involved in ergosterol biosynthesis and two genes that
code for 1,3-β-D-glucan synthase [12]. These findings help us
understand why there is evidence that caspofungin inhibits
glucan synthase activity of R. oryzae. 1,3-β-D-glucan is a small
part of the Mucorales cell wall and echinocandins are the
only antifungal to target the cell wall – most target the cell
memebrane. Thus, echinocandins, may be considered during
failure as an additional component of salvage therapy [12].
This patient was offered a combination of amphotericin B
deoxycholate plus caspofungin based on studies of rescue
therapy [13] as a last measure. However, she ultimately died due
the mold infection. From the time of her diagnosis, she lived
approximately six months.
Rhinocerebral mucormycosis is invasive and carries a poor
prognosis. Diabetes mellitus is a major risk factor and its
incidence is increasing globally, so patients presenting with
uncontrolled diabetes should be investigated for possible
mucormycosis. There is not a specific treatment duration.
It depends on clinical evaluation of the affected area and the
presence of the healing process after multiple debridements.
Amphotericin B or isavuconazonium sulfate is good initial
treatment if it is combined with surgical removal of necrotic
tissue. Combined therapy with an echinocandin may be an
efficacious and less toxic alternative for maintenance therapy.
Infections with Mucorales are present worldwide. It has been
well documented in Europe, India, Japan and the United States
[3,6,14,15]. More recent documentation of cases has come
from Burkina Faso, Iran and Taiwan [16-18]. There has been
a documented predilection for mucormycosis from August to
October/November. One study was from Japan, which has its
typhoon season at that time, but Iran and Israel, with more arid
climates, also found a higher incidence during that time period
[17,19,20]. As communities in the US become increasingly
international, diabetes becomes more prevalent and solid organ
transplants are performed more frequently, it is important
to recognize the need to expand the differential diagnoses to
include mucormoycosis, accordingly.
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